Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial-Reference-Cited by-同舟云学术

Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial

Published:2024-09 Issue:1 Volume:120 Page:49-58
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Yasar Binnaz,Suh Yae-Eun,Chapman Ewan,Nicholls Luke,Henderson Daniel,Jones Caroline,Morrison Kirsty,Wells Emma,Henderson Julia,Meehan Carole,Sohaib Aslam,Taylor Helen,Tree Alison,van As Nicholas

Funder

Royal Marsden NHS Foundation Trust

Publisher

Elsevier BV

Reference35 articles.

1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial;Beckendorf;Int J Radiat Oncol Biol Phys,2011

3. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomised controlled trial;Dearnaley;Lancet Oncol,2014

4. Oncologic and functional outcomes after radical prostatectomy for high or very high risk prostate cancer: European validation of the current NCCN® guideline;Pompe;J Urol,2017

5. 10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional versus hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016);Syndikus;J Clin Oncol,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Curative Stereotactic Body Radiation Therapy for Prostate Cancer, There Is a High Possibility That 45 Gy in Five Fractions Will Not Be Tolerated without a Hydrogel Spacer;Cancers;2024-04-11